About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2025 Clareo Health. All rights reserved.

COMPLETEDPhase 2

Ribavirin Dose Optimization for the Treatment of Hepatitis C

Ribavirin Dose Optimization for the Treatment of Hepatitis C: A Pilot Study

NCT01289496•Centre hospitalier de l'Université de Montréal (CHUM)

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Chronic Hepatitis C

Interventions

Peg-interferon alpha-2a, Ribavirin

Locations

1

Canada

Locations (1)

Centre hospitalier de l'Université de Montréal

Montreal, Quebec, Canada

Key Dates

Start Date

February 1, 2011

Primary Completion Date

August 1, 2013

Completion Date

August 1, 2013

Last Updated

February 26, 2014

Related Studies

COMPLETEDPhase 2

Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C. CINAM

NCT00199719

Chronic Hepatitis C

COMPLETEDPhase 4

Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital

NCT06922643

Chronic Hepatitis C

Changes in Liver Fibrosis, Lipid Profile and Insulin Resistance in HCV Patients Who Received Antiviral Therapy

NCT03612973

Chronic Hepatitis c

TERMINATEDPhase 3

Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV

NCT01866930

Chronic Hepatitis C Infection

Treatment of HCV-Infected Recent Injection Drug Users in U.S. Liver Clinics

NCT05895448

Chronic Hepatitis CPeople Who Inject Drugs

COMPLETEDPhase 3

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

NCT02219490

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

View all related studies

Sponsors

Lead Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Collaborators

Hoffmann-La Roche
Centre de Recherche du Centre Hospitalier de l'Université de Montréal

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 26, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions